Systemic Thrombolysis in Acute Stroke After Protamine-Reversal of Anticoagulation with Low-Molecular-Weight Heparin

AuthorDaniel Bereczki Jren
AuthorZoltan Simonyen
AuthorZoltan Szakacsen
AuthorGeza Szilagyien
Issued Date2016-10-01en
AbstractIntroduction: Intravenous thrombolysis may be withheld due to current exclusion criteria even if the patient arrives at hospital in time. However, under certain circumstances, some of these contraindications could be eliminated. Case Presentation: We report a systemic thrombolysis after reversal of anticoagulation with protamine sulfate in an acute stroke patient with suspected subacute non-ST-segment elevation myocardial infarction (NSTEMI) receiving full-dose low-molecular-weight heparin (LMWH). Conclusions: Considering the fact that only less than 10% of all acute strokes are eligible for intravenous thrombolysis, in particular circumstances and weighing a risk-benefit ratio, elimination of certain exclusion criteria could be a reasonable method to decrease the number of patients who currently fail to receive adequate treatment.en
DOIhttps://doi.org/10.5812/archneurosci.35202en
KeywordThrombolytic Therapyen
KeywordStrokeen
KeywordLow-Molecular-Weight Heparinen
KeywordProtamine Sulfateen
PublisherBrieflandsen
TitleSystemic Thrombolysis in Acute Stroke After Protamine-Reversal of Anticoagulation with Low-Molecular-Weight Heparinen
TypeCase Reporten

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
20585-pdf.pdf
Size:
69.58 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF